Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Armstrong

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Cancer Biology & Therapy|September 26, 2003
EpCAM: A new therapeutic target for an old cancer antigenAndrew Armstrong, Stephen L Eck
Journal of Behavioral Addictions|September 28, 2016
Observable indicators and behaviors for the identification of problem gamblers in venue environmentsPaul Delfabbro, Anna Thomas, Andrew Armstrong
Journal of Gambling Studies|May 13, 2017
Gender Differences in the Presentation of Observable Risk Indicators of Problem GamblingPaul Delfabbro, Anna Thomas, Andrew Armstrong
Journal of Evolutionary Biology|January 31, 2019
Inferring the potentially complex genetic architectures of adaptation, sexual dimorphism and genotype by environment interactions by partitioning of mean phenotypesAndrew Armstrong, Nathan W Anderson, Heath Blackmon
Urologic Oncology|February 7, 2012
Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancerJeffrey Peppercorn, Andrew Armstrong, David W Zaas, et al.
BMJ Case Reports|July 10, 2025
Improvement of bullous pemphigoid following salvage radiation in PSA-recurrent prostate cancer: a potential paraneoplastic associationMichael Shen Lee, Donna Aline Culton, Ryan Everett Fecteau, et al.
BMJ Case Reports|October 5, 2022
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenomaKatelyn Nazaneen Seale, Matthew K Labriola, Xiaoyin Sara Jiang, et al.
Molecular and Cellular Biochemistry|February 9, 2022
Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progressionMuhammad R Haque, Usman Barlass, Andrew Armstrong, et al.
BMJ Case Reports|February 23, 2024
Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate CancerJohn S Wang, Terence Wong, Kevin A Wu, et al.
Pharmaceutical Development and Technology|May 3, 2014
Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assayKalliopi Dodou, Andrew Armstrong, Ivan Kelly, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Cancer Biology & Therapy|September 26, 2003
EpCAM: A new therapeutic target for an old cancer antigenAndrew Armstrong, Stephen L Eck
Journal of Behavioral Addictions|September 28, 2016
Observable indicators and behaviors for the identification of problem gamblers in venue environmentsPaul Delfabbro, Anna Thomas, Andrew Armstrong
Journal of Gambling Studies|May 13, 2017
Gender Differences in the Presentation of Observable Risk Indicators of Problem GamblingPaul Delfabbro, Anna Thomas, Andrew Armstrong
Journal of Evolutionary Biology|January 31, 2019
Inferring the potentially complex genetic architectures of adaptation, sexual dimorphism and genotype by environment interactions by partitioning of mean phenotypesAndrew Armstrong, Nathan W Anderson, Heath Blackmon
Urologic Oncology|February 7, 2012
Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancerJeffrey Peppercorn, Andrew Armstrong, David W Zaas, et al.
BMJ Case Reports|July 10, 2025
Improvement of bullous pemphigoid following salvage radiation in PSA-recurrent prostate cancer: a potential paraneoplastic associationMichael Shen Lee, Donna Aline Culton, Ryan Everett Fecteau, et al.
BMJ Case Reports|October 5, 2022
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenomaKatelyn Nazaneen Seale, Matthew K Labriola, Xiaoyin Sara Jiang, et al.
Molecular and Cellular Biochemistry|February 9, 2022
Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progressionMuhammad R Haque, Usman Barlass, Andrew Armstrong, et al.
BMJ Case Reports|February 23, 2024
Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate CancerJohn S Wang, Terence Wong, Kevin A Wu, et al.
Pharmaceutical Development and Technology|May 3, 2014
Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assayKalliopi Dodou, Andrew Armstrong, Ivan Kelly, et al.
Pageof 3